Neumora Therapeutics is trading 5.65% down at $0.78 on September 16, 2026, with the move appearing primarily sector-driven amid broader biotech weakness. - The decline follows another sharp drop of 16.82% in the previous session; no new company-specific announcement has been identified. - Biotech stocks are weaker amid disappointing clinical-trial news and cautious sentiment. - The latest identifiable update was its August second-quarter report and pipeline update; live volume data was unavailable.